195 related articles for article (PubMed ID: 32532788)
1. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V; Zecchetto C; Santoro R; Simionato F; Sabbadini F; Mangiameli D; Piro G; Cavaliere A; Deiana M; Valenti MT; Bazan D; Fedele V; Lonardi S; Melisi D
Clin Cancer Res; 2020 Sep; 26(17):4661-4669. PubMed ID: 32532788
[TBL] [Abstract][Full Text] [Related]
2. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
3. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
4. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
[TBL] [Abstract][Full Text] [Related]
5. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
[TBL] [Abstract][Full Text] [Related]
6. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Yu HY; Lee CY; Lin LG; Chao Y; Li CP
J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
8. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
9. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
12. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
Hyung J; Kim I; Kim KP; Ryoo BY; Jeong JH; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Yoo C
JAMA Oncol; 2023 May; 9(5):692-699. PubMed ID: 36951834
[TBL] [Abstract][Full Text] [Related]
13. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
[TBL] [Abstract][Full Text] [Related]
14. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
16. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
Tang CY; Yang SH; Li CP; Su YY; Chiu SC; Bai LY; Shan YS; Chen LT; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chiang NJ; Chou WC
Pancreatology; 2024 Jun; 24(4):600-607. PubMed ID: 38565467
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
[TBL] [Abstract][Full Text] [Related]
18. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract][Full Text] [Related]
19. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
[TBL] [Abstract][Full Text] [Related]
20. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]